Temgésic Uses
How old is patient?
sponsored
Uses
Dosage
Side effects
Pregnancy
Overdose
Actions

What is Temgésic?

Temgésic is an opioid medication, sometimes called a narcotic.

This medication guide provides information about the Temgésic brand of Temgésic injection. Temgésic is another brand of Temgésic injection that is used to treat moderate to severe pain.

Temgésic is used to treat opioid addiction. Temgésic is not for use as a pain medication.

Temgésic is given to people who have started addiction treatment with an oral form of Temgésic placed under the tongue or inside the cheek (such as Suboxone or Temgésic).

Temgésic is available only in a certified healthcare setting under a special program. You will not be able to give yourself this medicine.

Temgésic may also be used for purposes not listed in this medication guide.

Temgésic indications

sponsored

Temgésic is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal Temgésic-containing product (i.e., doses of no more than 8 mg per day of Temgésic or Suboxone sublingual tablet equivalent or generic equivalent).

Temgésic should be used as part of a complete treatment program to include counseling and psychosocial support.

Temgésic is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on Temgésic 8 mg per day or less of a Temgésic or Suboxone sublingual tablet equivalent or generic equivalent.

How should I use Temgésic?

Use Temgésic patch as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Temgésic patch.

Uses of Temgésic in details

sponsored

Use: Labeled Indications

Opioid use disorder:

Extended-release injection: Maintenance treatment of moderate to severe opioid use disorder in patients who have initiated treatment with 8 to 24 mg of a transmucosal Temgésic-containing product, followed by dose adjustment for a minimum of 7 days.

Subdermal implant: Maintenance treatment of opioid use disorder in patients who have achieved and sustained prolonged clinical stability on low to moderate doses (≤8 mg/day) of a transmucosal Temgésic-containing product for 3 months or longer with no need for supplemental dosing or adjustments

Sublingual tablet: Medically supervised withdrawal and maintenance treatment of opioid use disorder.

Limitations of use: Temgésic should be used as part of a complete treatment program to include counseling and psychosocial support.

Pain management:

Buccal film, transdermal patch: Management of pain severe enough to require around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Immediate-release injection: Management of pain severe enough to require an opioid analgesic and for which treatments are inadequate

Limitations of use: Reserve Temgésic for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products, immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Temgésic buccal film and transdermal patch are not indicated as an as needed analgesic.

Off Label Uses

Opioid withdrawal in heroin-dependent hospitalized patients (immediate-release injection)

Data from a limited number of patients studied who received Temgésic parenterally for opioid withdrawal during hospitalization for an acute medical problem suggests that Temgésic is safe when used in this setting; Additional data may be necessary to further define the role of Temgésic in the management of postoperative pain as a perineural adjunct.

Temgésic description

sponsored

Temgésic transdermal patch is available in three strengths: Temgésic 5 mg contains 5 mg Temgésic in a drug-containing matrix that releases a nominal 5 micrograms of Temgésic per hour over 7 days.

Temgésic 10 mg contains 10 mg Temgésic in a drug-containing matrix that releases a nominal 10 micrograms of Temgésic per hour over 7 days.

Temgésic 20 mg contains 20 mg Temgésic in a drug-containing matrix that releases a nominal 20 micrograms of Temgésic per hour over 7 days.

Temgésic is a rectangular or square, transdermal patch consisting of a protective liner and functional layers including a Temgésic-containing adhesive matrix.

Excipients/Inactive Ingredients: Levulinic acid, oleyl oleate, povidone (PVP), polyacrylate (dry solids), polyethylene terephthalate (PET).

Temgésic dosage

Dosage and Titration: The lowest Temgésic 5 mg should be used as the initial dose in all patients.

During initiation, titration, and treatment with Temgésic, patients may continue their existing NSAID or acetaminophen regimen as needed.

The dose of Temgésic should not be increased at less than 3-day intervals when steady-state levels are attained. Changes in Temgésic dosage may be individually titrated based on the need for supplemental PRN analgesia and the patient's analgesic response to Temgésic.

To increase the dose, a larger patch should replace the patch that is currently being worn, or a combination of patches should be applied in different places to achieve the desired dose. It is recommended that no more than two patches be applied at the same time, regardless of patch strength.

Titration should continue every 3-7 days until adequate analgesia is achieved.

If adequate pain control cannot be achieved with Temgésic, therapy should be discontinued and the patient converted to an appropriate analgesic regimen as determined by a physician.

Discontinuation: After removal of Temgésic, plasma concentrations decrease gradually. This should be considered when therapy with Temgésic is to be followed by other opioids. As a general rule, a subsequent opioid should not be administered within 24 hours after removal of Temgésic.

Conversion From Opioids: Temgésic can be used as an alternative to treatment with other opioids. Such patients should be started on the lowest available dose Temgésic 5 mg and continue taking short-acting supplemental analgesics during titration, as required.

Children: The safety and efficacy of Temgésic in patients under 18 years of age has not been established.

Renal Impairment: No special dose adjustment of Temgésic is necessary in patients with renal impairment.

Hepatic Impairment: There is no need for dosage adjustment when using Temgésic in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment may accumulate Temgésic during Temgésic treatment. Consideration of alternate therapy should be given, and Temgésic should be used with caution, if at all, in such patients.

Elderly: No dosage adjustment of Temgésic is required in elderly patients.

Administration: Temgésic should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. Temgésic should be applied to a relatively hairless or nearly hairless skin site. If none are available, the hair at the site should be clipped with scissors, not shaven.

Application sites should be rotated whenever a patch is replaced or added. Application sites should be re-used at no less than 3-week intervals.

If the application site must be cleaned, it should be done with clear water only. Soaps, alcohol, oils, lotions, or abrasive devices should not be used. The skin must be dry before the transdermal patch is applied.

Temgésic should be worn continuously for 7 days. Temgésic should be pressed firmly in place at the application site, making sure contact is complete, especially around the edges. If the edges of the patch begin to peel off, the edges may be taped down with suitable skin tape. If a transdermal patch falls off, a new one should be applied. Bathing, showering, or swimming should not affect the patch. While wearing Temgésic, patients should be advised to avoid exposing the Temgésic site to direct external heat sources such as heating pads, electric blankets, heat lamps, etc., as an increase in absorption of Temgésic may occur. The effects of the use of Temgésic while in hot tubs and saunas have not been studied.

Patch Application: Applying the Patch: Step 1: Each patch is sealed in a pouch. Just before use, open the pouch by tearing where indicated. Take out the patch.

Step 2: The sticky side of the patch is covered with a silvery protective foil. Carefully peel off half the foil. Try not to touch the sticky part of the patch.

Step 3: Stick the patch onto the chosen area of the skin and remove the remaining foil.

Step 4: Press the patch against the skin with the palm of the hand and count slowly to 30. Make sure that the whole patch is in contact with the skin, especially at the edges.

Step 5: Find a calendar that will help to remember to change the patch every 7th day. Mark the day when the first patch was put on and make a note of the time of day.

Wearing the Patch: Temgésic should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. Application sites should be re-used at no less than 3-week (21 days) intervals.

If a transdermal patch falls off before it needs changing, a new patch should be applied.

Changing the Patch: Take the old patch off.

Fold it in half with the sticky side inwards. Put the used patch into its original pouch. Then put the pouch in the bin used for the household rubbish. Even used patches contain some active medicine that may harm children or animals, so make sure the used patches are always kept well away from them. Throw it away carefully, out of the reach and sight of children.

Stick a new patch on a different appropriate skin site. The patient should not apply a new patch to the same site for the following 3-4 weeks.

Mark the day and time of application on the calendar.

Remember to change the patch at the same time of day each time.

Temgésic interactions

See also:
What other drugs will affect Temgésic?

sponsored

Drug interactions common to other potent opioid analgesics also may occur with Temgésic (Temgésic). Particular care should be taken when Temgésic (Temgésic) is used in combination with central nervous system depressant drugs. Although specific information is not presently available, caution should be exercised when Temgésic (Temgésic) is used in combination with MAO inhibitors. There have been reports of respiratory and cardiovascular collapse in patients who received therapeutic doses of diazepam and Temgésic (Temgésic). A suspected interaction between Temgésic (Temgésic) and phenprocoumon resulting in purpura has been reported.

CYP3A4 Inhibitors: Since the metabolism of Temgésic is mediated by the CYP3A4 isozyme, coadministration of drugs that inhibit CYP3A4 activity may cause decreased clearance of Temgésic. Thus patients coadministered with inhibitors of CYP3A4 such as macrolide antibiotics (e.g., erythromycin), azole antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritanovir) while receiving Temgésic (Temgésic) should be carefully monitored and dosage adjustment made if warranted.

CYP3A4 Inducers: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and as such may cause increased clearance of Temgésic. Caution is advised when administering Temgésic (Temgésic) to patients receiving these medications and if necessary dose adjustments should be considered

Temgésic side effects

See also:
What are the possible side effects of Temgésic?

The following adverse reactions are discussed in more detail in other sections of the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of Temgésic was evaluated in 848 opioid-dependent subjects. In these studies, there was a total of 557 subjects who received at least 6 monthly SC injections of Temgésic and 138 subjects who received 12 monthly SC injections. Adverse events led to premature discontinuation in 4% of the group receiving Temgésic compared with 2% in the placebo group (13-0001, NCT02357901).

In the Phase 3 open-label study (13-0003, NCT02510014), adverse events leading to drug dose reductions were reported in 7.3% of subjects receiving Temgésic.

Table 1. Total Subjects Exposed to Temgésic
Study 13-0001 (NCT02357901)

Up to 6 Injections

 Study 13-0003 (NCT02510014) Total Subjects Exposed To

Temgésic

*Not included in total subjects exposed to Temgésic

† FLEX = 300 mg initial dose with an option to receive either 100 mg or 300 mg for subsequent dosing per clinician's discretion

‡ = Not included in total unique subjects exposed to Temgésic, already accounted for in Study 13-0001 section of table
Roll-Over

Up to 6 Injections

 De-Novo

Up to 12 Injections
Temgésic 300/100 mg Temgésic 300/300 mg Placebo From Temgésic 300/100 mg To

Temgésic 300/Flex†

 From Temgésic 300/300 mg To

Temgésic 300/Flex†

 From Placebo

To

Temgésic 300/Flex†

 Temgésic 300/Flex
N = 203 N = 201 N = 100* N = 112‡ N = 113‡ N= 32 N = 412 N = 848

Table 2 shows the non-injection site-related adverse reactions (ADRs) for the groups receiving Temgésic 300/300 mg (6 doses of 300 mg SC injections) 300/100 mg (300 mg SC injections for the first two doses followed by 4 doses of 100 mg SC injections) and placebo (volume-matched ATRIGEL® delivery system subcutaneous injections) reported following administration in the 6 month, double-blind, placebo-controlled study. The systemic safety profile for Temgésic, given by a healthcare provider in clinical trials, was consistent with the known safety profile of transmucosal Temgésic. Common adverse reactions associated with Temgésic included constipation, nausea, vomiting, abnormal liver enzymes, headache, sedation and somnolence. Dose dependent hepatic effects observed in the Phase 3, double-blind study (13-0001, NCT02357901) included the incidence of ALT more than 3 times the upper limit of normal (> 3 × ULN) in 12.4%, 5.4%, and 4.0% of the Temgésic 300/300-mg, Temgésic 300/100-mg, and placebo groups, respectively. The incidence of AST > 3 × ULN was 11.4%, 7.9%, and 1.0%, respectively. Adverse drug reactions [by MedDRA Preferred Terms (PT)] reported in at least 2% of subjects receiving Temgésic are grouped by System Organ Class (SOC).

Table 2. Adverse Reactions for Phase 3 Double-Blind Study: ≥2% of Subjects Receiving Temgésic
System Organ Class

Preferred Term

 PLACEBO Temgésic

300/100 mg

 Temgésic

300/300 mg
Count (%) Count (%) Count (%)

*There were no cases of serious liver injury attributed to study drug.
Total N = 100 N = 203 N = 201
Gastrointestinal disorders 12 (12%) 51 (25.1%) 45 (22.4%)
Constipation 0 19 (9.4) 16 (8)
Nausea 5 (5) 18 (8.9) 16 (8)
Vomiting 4 (4) 19 (9.4) 11 (5.5)
General disorders and administration site conditions 17 (17%) 40 (19.7%) 49 (24.4%)
Fatigue 3 (3) 8 (3.9) 12 (6)
Investigations* 2 (2%) 21 (10.3%) 19 (9.5%)
Alanine aminotransferase increased (ALT) 0 2 (1) 10 (5)
Aspartate aminotransferase increased (AST) 0 7 (3.4) 9 (4.5)
Blood creatine phosphokinase increased (CPK) 1 (1) 11 (5.4) 5 (2.5)
Gamma-glutamyl transferase increased (GGT) 1 (1) 6 (3) 8 (4)
Nervous system disorders 7 (7%) 35 (17.2%) 25 (12.4%)
Headache 6 (6) 19 (9.4) 17 (8.5)
Sedation 0 7 (3.4) 3 (1.5)
Dizziness 2 (2) 5 (2.5) 3 (1.5)
Somnolence 0 10 (4.9) 4 (2)

Table 3 shows the injection site-related adverse events reported by ≥2 subjects in the Phase 3 studies. Most injection site adverse drug reactions (ADRs) were of mild to moderate severity, with one report of severe injection site pruritus. None of the injection site reactions were serious. One reaction, an injection site ulcer, led to study treatment discontinuation.

Table 3. Injection Site Adverse Drug Reactions Reported by ≥2 Subjects in the Phase 3 Double-Blind Study

*Patients received SUBOXONE film for a run-in period before they switched to Temgésic injection.
Preferred term, n (%) 13-0001 (Ph3DB) 13-0003 (Ph3OL) All

Phase 3*
Roll–over De-novo
Temgésic

300/300

(N = 201)

 Temgésic 300/100

(N = 203)

 Placebo

(N = 100)

 Temgésic 300 →

Temgésic

300/Flex

(N = 113)

 Temgésic 100 →

Temgésic

300/Flex

(N = 112)

 Placebo →

Temgésic 300/Flex

(N = 32)

 Temgésic 300/Flex

(N = 412)

 Total

Temgésic (N = 848)
Subjects with any injection site reactions 38 (18.9%) 28 (13.8%) 9 (9.0%) 6 (5.3%) 13 (11.6%) 2 (6.3%) 61 (14.8%) 140 (16.5%)
Injection site pain 12 (6.0%) 10 (4.9%) 3 (3.0%) 4 (3.5%) 2 (1.8%) 2 (6.3%) 33 (8.0%) 61 (7.2%)
Injection site pruritus 19 (9.5%) 13 (6.4%) 4 (4.0%) 2 (1.8%) 6 (5.4%) 1 (3.1%) 17 (4.1%) 56 (6.6%)
Injection site erythema 6 (3.0%) 9 (4.4%) 0 1 (0.9%) 4 (3.6%) 0 21 (5.1%) 40 (4.7%)
Injection site induration 2 (1.0%) 2 (1.0%) 0 0 1 (0.9%) 0 7 (1.7%) 12 (1.4%)
Injection site bruising 2 (1.0%) 2 (1.0%) 0 0 0 0 2 (0.5%) 6 (0.7%)
Injection site swelling 1 (0.5%) 2 (1.0%) 0 1 (0.9%) 1 (0.9%) 0 1 (0.2%) 6 (0.7%)
Injection site discomfort 1 (0.5%) 1 (0.5%) 0 0 0 0 3 (0.7%) 5 (0.6%)
Injection site reaction 1 (0.5%) 0 0 0 3 (2.7%) 0 1 (0.2%) 5 (0.6%)
Injection site cellulitis 0 1 (0.5%) 0 0 0 0 2 (0.5%) 3 (0.4%)
Injection site infection 1 (0.5%) 0 1 (1.0%) 0 0 0 2 (0.5%) 3 (0.4%)

Longer-term experience

In an interim analysis of the ongoing open-label long-term safety study (13-0003), safety was evaluated for up to 12 injections over the course of a year. Adverse events were reported for 432 of 669 subjects during the treatment period. The overall adverse event profile was similar to the double-blind trial described above.

Postmarketing Experience

The most frequently reported systemic postmarketing adverse event observed with Temgésic sublingual tablets was drug misuse or abuse. The most frequently reported systemic postmarketing adverse event with Temgésic/naloxone sublingual tablets and film was peripheral edema.

The following adverse reactions have been identified during post-approval use of Temgésic. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Serotonin syndrome: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.

Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.

Anaphylaxis: Anaphylaxis has been reported with ingredients contained in Temgésic.

Androgen deficiency: Cases of androgen deficiency have occurred with chronic use of opioids.

Temgésic contraindications

See also:
What is the most important information I should know about Temgésic?

Using Temgésic improperly will increase your risk of serious side effects or death. Even if you have used other narcotic medications, you may still have serious side effects from Temgésic. Follow all dosing instructions carefully.

Like other narcotic medicines, Temgésic can slow your breathing. Death may occur if breathing becomes too weak.

Never crush a tablet or other pill to mix into a liquid for injecting the drug into your vein. This practice has resulted in death with the misuse of Temgésic and similar prescription drugs.

Wear a medical alert tag or carry an ID card stating that you take Temgésic, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are being treated for narcotic addiction.

Avoid drinking alcohol, which can increase some of the side effects of Temgésic. Using too much of this medicine in addition to drinking alcohol can cause death.

Do not stop using Temgésic suddenly after long-term use, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using Temgésic. You may need to use less and less before you stop the medication completely.

This medication may impair your thinking or reactions. Avoid driving or operating machinery until you know how Temgésic will affect you.



Active ingredient matches for Temgésic:

Buprenorphine in France.


Unit description / dosage (Manufacturer)Price, USD
Injectable; Injection; Buprenorphine Hydrochloride 0.3 mg / ml
Tablet; Sublingual; Buprenorphine Hydrochloride 0.2 mg
Tablet; Sublingual; Buprenorphine Hydrochloride 0.4 mg
Temgesic 200 mcg x 50's
Temgesic 300 mcg/1 mL x 1 mL x 5's
Temgesic 0.2 mg x 10 x 5's
Temgesic 0.3 mg/1 mL x 1 mL x 5's$ 52.13
Temgesic 0.2 mg x 50's$ 57.35

List of Temgésic substitutes (brand and generic names):

Talgesic
Talgesic 0.6 mg Injection (Indus Pharma Pvt. Ltd.)$ 0.09
Tecnopren (Mexico)
Temgesic 0.2mg (Austria, Luxembourg, Switzerland)
Temgesic 0.3mg/ml (Luxembourg, Switzerland)
Temgesic 0.4mg (Austria, Switzerland)
Temgesic Forte (Germany)
Tablet, Film-Coated; Oral; Buprenorphine Hydrochloride
Temgesic Sublingual
Tablet; Sublingual; Buprenorphine Hydrochloride 0.2 mg
Tablet; Sublingual; Buprenorphine Hydrochloride 0.4 mg
Temgesic-nX
Tephine (United Kingdom)
Tidigesic (India)
TIDIGESIC Injection / 0.3mg per ml / 1ml units (Sun Pharmaceutical Industries Ltd.)$ 0.14
TIDIGESIC Tablet Sub - lingual / 0.2mg / 10 units (Sun Pharmaceutical Industries Ltd.)$ 0.30
TIDIGESIC Injection / 0.3mg per ml / 2ml units (Sun Pharmaceutical Industries Ltd.)$ 0.18
Tidigesic 0.2mg SL-TAB / 10 (Sun Pharmaceutical Industries Ltd.)$ 0.30
Tidigesic 0.3mg/ml INJ / 1ml (Sun Pharmaceutical Industries Ltd.)$ 0.14
Tidigesic 0.3mg/ml INJ / 2ml (Sun Pharmaceutical Industries Ltd.)$ 0.18
0.2 mg x 10's (Sun Pharmaceutical Industries Ltd.)$ 0.30
0.3 mg x 1 mL x 1ml (Sun Pharmaceutical Industries Ltd.)$ 0.14
0.3 mg x 1 mL x 2ml (Sun Pharmaceutical Industries Ltd.)$ 0.18
Tidigesic 0.3 mg Injection (Sun Pharmaceutical Industries Ltd.)$ 0.14
Tidigesic 0.6 mg Injection (Sun Pharmaceutical Industries Ltd.)$ 0.09
Tidigesic 0.2 mg Tablet (Sun Pharmaceutical Industries Ltd.)$ 0.03
TIDIGESIC 0.3MG INJECTION 1 vial / 1 ML injection each (Sun Pharmaceutical Industries Ltd.)$ 0.15
TIDIGESIC 0.3MG INJECTION 1 vial / 2 ML injection each (Sun Pharmaceutical Industries Ltd.)$ 0.17
TIDIGESIC sublingual tab 0.2 mg x 10's (Sun Pharmaceutical Industries Ltd.)$ 0.30
TIDIGESIC inj 0.3 mg x 1 mL x 1ml (Sun Pharmaceutical Industries Ltd.)$ 0.14
TIDIGESIC inj 0.3 mg x 1 mL x 2ml (Sun Pharmaceutical Industries Ltd.)$ 0.18
Tidigesic 0.2mg Tablet (Sun Pharmaceutical Industries Ltd.)$ 0.03
Transtec (Austria, Belgium, Chile, Colombia, Croatia (Hrvatska), Czech Republic, Denmark, Hungary, Ireland, Italy, Luxembourg, Mexico, Netherlands, Peru, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, United Kingdom)
Patch; Topical; Buprenorphine 35 mcg / h
Patch; Topical; Buprenorphine 52.5 mcg / h
Patch; Topical; Buprenorphine 70 mcg / h
Transtec 35µg/h (Austria, Hungary, Luxembourg, Switzerland)
Transtec 52.5µg/h (Austria, Hungary, Luxembourg, Switzerland)
Transtec 70µg/h (Austria, Hungary, Luxembourg, Switzerland)
Transtec Pro (Germany)
Triquisic (Austria, Slovenia)
Vetergesic (France, Germany, Norway, Sweden, United Kingdom)
Vetergesic 0.3 mg/ml (France, Netherlands)
Vetergesic chiens, chats (Belgium)
Vetergesic vet (Iceland, Poland)
Zalban (Japan)

See 437 substitutes for Temgésic

References

  1. DailyMed. "BUPRENORPHINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "buprenorphine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "buprenorphine". http://www.drugbank.ca/drugs/DB00921 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Temgésic are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Temgésic. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 16 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

More about Temgésic

  • Temgésic generic and brand names

    • Clinician Information

  • Administration
  • Breastfeeding
  • Contraindications
  • Interactions
  • Pharmacology
  • Precautions
  • Warnings

    • Share on Facebook Tweet

    | Privacy Policy
    This site does not supply any medicines. It contains prices for information purposes only.
    © 2003 - 2024 ndrugs.com All Rights Reserved